← Back to Screener
Genprex, Inc. Common Stock (GNPX)
Price$0.72
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-87.33%
Price vs S&P 500 (4W)-21.89%
VGM Score9.46
Market Capitalization$7.78M
All Metrics
Book Value / Share (Quarterly)$1.87
P/TBV (Annual)0.66x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.58
Price vs S&P 500 (YTD)-69.38%
EPS (TTM)$-15.91
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-15.91
EPS (Annual)$-263.49
ROI (Annual)-1303.03%
Cash / Share (Quarterly)$2.00
ROA (Last FY)-511.87%
EBITD / Share (TTM)$-6.19
ROE (5Y Avg)-386.77%
Cash Flow / Share (Annual)$-4.65
P/B Ratio0.46x
P/B Ratio (Quarterly)0.97x
Net Income / Employee (Annual)$-1,623,900
Net Interest Coverage (TTM)-1404.94x
ROA (TTM)-176.74%
EPS Incl Extra (Annual)$-263.49
Current Ratio (Annual)3.84x
Quick Ratio (Quarterly)5.38x
3-Month Avg Trading Volume0.83M
52-Week Price Return-95.39%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.71
52-Week High$55.00
EPS Excl Extra (Annual)$-263.49
Tangible BV CAGR (5Y)19.46%
26-Week Price Return-73.74%
Quick Ratio (Annual)3.60x
13-Week Price Return-63.06%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.61x
Enterprise Value$-10.27M
Book Value / Share Growth (5Y)-39.02%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.38
3-Month Return Std Dev65.75%
Net Income / Employee (TTM)$-1,286,600
ROE (Last FY)-1303.03%
EPS Basic Excl Extra (Annual)$-263.49
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-15.91
Receivables Turnover (Annual)0.00x
ROI (TTM)-247.33%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.87
Price vs S&P 500 (52W)-123.54%
Year-to-Date Return-57.99%
5-Day Price Return-5.29%
EPS Normalized (Annual)$-263.49
ROA (5Y Avg)-200.22%
Month-to-Date Return-5.68%
Cash Flow / Share (TTM)$-0.61
EBITD / Share (Annual)$-264.20
ROI (5Y Avg)-386.77%
EPS Basic Excl Extra (TTM)$-15.91
P/TBV (Quarterly)1.06x
P/B Ratio (Annual)0.51x
Book Value / Share (Annual)$2.42
Price vs S&P 500 (13W)-73.72%
Beta-0.89x
Revenue / Share (TTM)$0.00
ROE (TTM)-247.33%
52-Week Low$0.72
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.64est. —
Analyst Recommendations
Jun 2025
Jul 2025
Aug 2025
Oct 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GNPXGenprex, Inc. Common Stock | — | — | F | $0.72 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Genprex Inc develops non-viral gene therapies for cancer and diabetes. The company's Oncoprex Delivery System uses lipid nanoparticles to deliver therapeutic genes, with its lead candidate Reqorsa under evaluation in three clinical trials for non-small cell and small cell lung cancer.